Patient-reported symptoms and burden of eosinophilic esophagitis: evidence from real-world clinical practice

被引:0
作者
Xu, Xiao [1 ,2 ]
Kwiatek, Justin [2 ]
Siddall, James [3 ]
Genofre, Eduardo [4 ]
Stirnadel-Farrant, Heide [5 ]
Katial, Rohit [2 ]
机构
[1] AstraZeneca, BioPharmaceut Market Access & Pricing, 200 Orchard Ridge Dr, Gaithersburg, MD 20878 USA
[2] AstraZeneca, BioPharmaceut Med, 200 Orchard Ridge Dr, Gaithersburg, MD 20878 USA
[3] Adelphi Real World, Bollington, Cheshire, England
[4] AstraZeneca, BioPharmaceut Med, Wilmington, DE USA
[5] AstraZeneca, BioPharmaceut Med, Cambridge, England
关键词
Eosinophilic esophagitis; Inflammatory disease; Real-world evidence; Health-related quality of life; Disease burden; QUALITY-OF-LIFE; RECOMMENDATIONS; MANAGEMENT; DIAGNOSIS; CHILDREN; ANXIETY; ADULTS; COSTS;
D O I
10.1186/s12876-024-03334-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundEosinophilic esophagitis is a chronic inflammatory disorder of the esophagus. This real-world study used patient and physician surveys to describe the clinical characteristics and disease burden of eosinophilic esophagitis-overall and in a subgroup of patients with dysphagia despite treatment.MethodsData analyzed in this study were collected in 2020 from US and EU patients with eosinophilic esophagitis. Eligible patients were aged >= 12 years with a diagnosis of eosinophilic esophagitis, had an esophageal count of >= 15 eosinophils/high-power field at diagnosis, and were currently prescribed treatment for eosinophilic esophagitis.ResultsOverall, 1001 patients were included, of whom 356 (36%) had dysphagia despite treatment. Demographics and clinical characteristics were similar in both populations. The severity of eosinophilic esophagitis was mild in more patients overall (69%) versus those with dysphagia despite treatment (48%). Patient disease history was similar in both populations, with some exceptions: common patient-reported symptoms were dysphagia (70% and 86%) and heartburn/acid reflux (55% and 49%), and common physician-reported symptoms were dysphagia (75% and 91%) and food impaction (46% and 52%). Treatment history was similar in both populations; overall, the most common treatments were proton pump inhibitors (83%) and topical corticosteroids (51%). Patients reported slightly more days with symptoms, higher impacts on activities of daily living, and slightly higher anxiety or depression in the dysphagia-despite-treatment population versus the overall population.ConclusionsEosinophilic esophagitis presents severe symptoms and comorbidities that substantially impact patients' well-being and quality of life. Greater awareness of and novel treatments for eosinophilic esophagitis are needed.
引用
收藏
页数:10
相关论文
共 23 条
[1]   Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand [J].
Anderson, P. ;
Benford, M. ;
Harris, N. ;
Karavali, M. ;
Piercy, J. .
CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) :3063-3072
[2]  
[Anonymous], 2022, Jorveza. (budesonide) package insert
[3]   Disease Burden and Unmet Need in Eosinophilic Esophagitis [J].
Bredenoord, Albert J. ;
Patel, Kiran ;
Schoepfer, Alain M. ;
Dellon, Evan S. ;
Chehade, Mirna ;
Aceves, Seema S. ;
Spergel, Jonathan M. ;
Shumel, Brad ;
Deniz, Yamo ;
Rowe, Paul J. ;
Jacob-Nara, Juby A. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (08) :1231-1241
[4]   What patients with eosinophilic esophagitis may not share with their providers: a qualitative assessment of online health communities [J].
Chang, Joy W. ;
Chen, Vincent L. ;
Rubenstein, Joel H. ;
Dellon, Evan S. ;
Wallner, Lauren P. ;
De Vries, Raymond .
DISEASES OF THE ESOPHAGUS, 2022, 35 (06)
[5]   Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference [J].
Dellon, Evan S. ;
Liacouras, Chris A. ;
Molina-Infante, Javier ;
Furuta, Glenn T. ;
Spergel, Jonathan M. ;
Zevit, Noam ;
Spechler, Stuart J. ;
Attwood, Stephen E. ;
Straumann, Alex ;
Aceves, Seema S. ;
Alexander, Jeffrey A. ;
Atkins, Dan ;
Arva, Nicoleta C. ;
Blanchard, Carine ;
Bonis, Peter A. ;
Book, Wendy M. ;
Capocelli, Kelley E. ;
Chehade, Mirna ;
Cheng, Edaire ;
Collins, Margaret H. ;
Davis, Carla M. ;
Dias, Jorge A. ;
Di Lorenzo, Carlo ;
Dohil, Ranjan ;
Dupont, Christophe ;
Falk, Gary W. ;
Ferreira, Cristina T. ;
Fox, Adam ;
Gonsalves, Nirmala P. ;
Gupta, Sandeep K. ;
Katzka, David A. ;
Kinoshita, Yoshikazu ;
Menard-Katcher, Calies ;
Kodroff, Ellyn ;
Metz, David C. ;
Miehlke, Stephan ;
Muir, Amanda B. ;
Mukkada, Vincent A. ;
Murch, Simon ;
Nurko, Samuel ;
Ohtsuka, Yoshikazu ;
Orel, Rok ;
Papadopoulou, Alexandra ;
Peterson, Kathryn A. ;
Philpott, Hamish ;
Putnam, Philip E. ;
Richter, Joel E. ;
Rosen, Rachel ;
Rothenberg, Marc E. ;
Schoepfer, Alain .
GASTROENTEROLOGY, 2018, 155 (04) :1022-+
[6]   ACG Clinical Guideline: Evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis (EoE) [J].
Dellon, Evan S. ;
Gonsalves, Nirmala ;
Hirano, Ikuo ;
Furuta, Glenn T. ;
Liacouras, Chris A. ;
Katzka, David A. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 (05) :679-692
[7]  
fda, 2022, FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder
[8]   Patient and caregiver perspective on pediatric eosinophilic esophagitis and newly developed symptom questionnaires [J].
Flood, Emuella M. ;
Beusterien, Kathleen M. ;
Amonkar, Mayur M. ;
Jurgensen, Cynthia H. ;
Dewit, Odile E. ;
Kahl, Lesley P. ;
Matza, Louis S. .
CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (12) :3369-3381
[9]   Quality of life in paediatric eosinophilic oesophagitis: what is important to patients? [J].
Franciosi, J. P. ;
Hommel, K. A. ;
DeBrosse, C. W. ;
Greenberg, A. B. ;
Greenler, A. J. ;
Abonia, J. P. ;
Rothenberg, M. E. ;
Varni, J. W. .
CHILD CARE HEALTH AND DEVELOPMENT, 2012, 38 (04) :477-483
[10]   Emerging therapies for eosinophilic esophagitis [J].
Greuter, Thomas ;
Hirano, Ikuo ;
Dellon, Evan S. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (01) :38-45